Keros Therapeutics (NASDAQ:KROS) Given New $15.00 Price Target at Piper Sandler

Keros Therapeutics (NASDAQ:KROS) had its target price decreased by Piper Sandler from $40.00 to $15.00 in a research note issued to investors on Friday morning,Benzinga reports. Piper Sandler currently has an overweight rating on the stock.

A number of other brokerages have also commented on KROS. Wedbush lowered shares of Keros Therapeutics from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $47.00 to $15.00 in a research report on Friday. Truist Financial decreased their target price on Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating for the company in a research report on Monday, December 23rd. Guggenheim reissued a “neutral” rating on shares of Keros Therapeutics in a research report on Friday. BTIG Research downgraded Keros Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, December 12th. Finally, Scotiabank dropped their target price on shares of Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating on the stock in a report on Thursday. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, Keros Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $52.56.

Keros Therapeutics Trading Up 3.2 %

Shares of NASDAQ:KROS opened at $10.86 on Friday. The company has a market capitalization of $439.91 million, a price-to-earnings ratio of -2.08 and a beta of 1.43. Keros Therapeutics has a 12 month low of $9.77 and a 12 month high of $73.00. The firm’s 50-day moving average is $37.51 and its 200 day moving average is $47.36.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The company had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company’s revenue for the quarter was up 4750.0% on a year-over-year basis. During the same period in the prior year, the company earned ($1.33) earnings per share. As a group, equities analysts forecast that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Institutional Investors Weigh In On Keros Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Point72 Asset Management L.P. boosted its stake in Keros Therapeutics by 155.9% in the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock worth $55,025,000 after purchasing an additional 577,220 shares in the last quarter. Alkeon Capital Management LLC lifted its stake in shares of Keros Therapeutics by 18.7% during the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock worth $110,194,000 after buying an additional 298,694 shares during the period. Parkman Healthcare Partners LLC grew its holdings in shares of Keros Therapeutics by 112.3% during the third quarter. Parkman Healthcare Partners LLC now owns 421,782 shares of the company’s stock valued at $24,493,000 after buying an additional 223,155 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of Keros Therapeutics by 814.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 223,704 shares of the company’s stock valued at $12,990,000 after acquiring an additional 199,245 shares during the period. Finally, FMR LLC raised its stake in Keros Therapeutics by 3.8% in the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company’s stock worth $284,493,000 after acquiring an additional 179,374 shares during the last quarter. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.